Comparative efficacy and safety of treatments for the management of overactive bladder: A systematic literature review and mixed treatment comparison
2013 Value in health
Maman, K. | Aballea, S. | Nazir, J. | Desroziers, K. | Neine, M. | Siddiqui, E. | Odeyemi, I. | Hakimi, Z. |
Overactive bladder (OAB) treatment guidelines recommend antimuscarinics as ?rst-line pharmacologic therapy. Mirabegron is a first-in-class beta-3 adrenoceptor agonist which is licensed for the treatment of OAB and has shown to be well tolerated and effective in the treatment of OAB symptoms. A systematic literature review and Mixed Treatment Comparisons (MTC) were performed to assess the efficacy and tolerability of OAB medications, and more specifically mirabegron 50 mg vs. antimuscarinics in patients with OAB.